BORA PHARMACEUTICALS LTD (6472) — Cash Flow Quality Index
BORA PHARMACEUTICALS LTD (6472) has a Cash Flow Quality Index of 14.11x as of March 2026. Operating cash flow of NT$568.46 Million exceeds net income of NT$40.29 Million, indicating high earnings quality where cash backs reported profits. Explore BORA PHARMACEUTICALS LTD cash conversion from operations to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
BORA PHARMACEUTICALS LTD Cash Flow Quality Index (2019–2025)
Historical Cash Flow Quality Index for BORA PHARMACEUTICALS LTD across 7 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 6472 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for BORA PHARMACEUTICALS LTD (2019–2025)
Year-by-year earnings quality comparison for BORA PHARMACEUTICALS LTD. For live market cap and the full company financial profile, see 6472 company net worth.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.97x | NT$4.24 Billion | NT$4.38 Billion | ▲ +388.9% |
| 2024 | 0.20x | NT$980.81 Million | NT$4.95 Billion | ▼ -82.6% |
| 2023 | 1.14x | NT$4.61 Billion | NT$4.06 Billion | ▲ +3.9% |
| 2022 | 1.09x | NT$2.01 Billion | NT$1.84 Billion | ▼ -9.5% |
| 2021 | 1.21x | NT$1.24 Billion | NT$1.02 Billion | ▲ +304.4% |
| 2020 | 0.30x | NT$177.79 Million | NT$595.40 Million | ▼ -60.7% |
| 2019 | 0.76x | NT$231.77 Million | NT$305.03 Million | — |